OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hepatology is 103. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
JHEP at a glance (October 2024)	2704
Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis	1595
Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver	1336
Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014	1139
The anti-fibrotic efficacy of Adelmidrol depends in the level of hepatic PPAR gama	1134
The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency	1002
Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis	944
Gut-liver crosstalk in hepatocellular carcinoma and non-selective beta-blockers: is there a link?	395
Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy	343
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B	326
Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece	314
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis	308
Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis	293
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease	277
Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients	274
Eliminating viral hepatitis one island at a time-the Hainan experience	260
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)	259
Assessing progress towards achieving regional hepatitis B control goal-nationwide serosurvey among children, Uzbekistan, 2022	252
PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes	244
The health economic outcomes of trial ACTG5360/MINMON	238
The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure	235
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction	229
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease	225
An explainable artificial intelligence model for prediction of high-risk non-alcoholic steatohepatitis	222
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers	218

Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona	215
Automation of hepatitis C screening through electronic health record algorithm	207
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021	202
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis	198
A new nuclear-erythroid-2-related factor 2 activator for the treatment of non-alcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices	196
Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making	196
Effect of housing temperature on non-alcoholic fatty liver disease development in C57BL/6N mice	195
Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD	193
Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan	191
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm	185
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study	180
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis	175
Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling	170
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis	170
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study	170
Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease	169
The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus	168
Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands	167
Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease	166
Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis	165
Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)	160
CyberLiver Animal Recognition Test (CL-ART): a novel remote monitoring tool to assess minimal hepatic encephalopathy	160
Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis	158
Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test	158
Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)	155
Endoscopic glue injection v/s endoscopic human thrombin injection for bleeding gastric varics -a randomized controlled trial	153
Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years’ experience in a tertiary referral center with genotyping facility	152
Neutrophil gelatinase-associated lipocalin predicts response to terlipressin and albumin in patients with hepatorenal syndrome	151
Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study	147
Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions	146
miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC	144
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis	142
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)	142
TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD	142
Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B	140
Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study	140
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease	140
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis	140
Reply to: Correspondence on “EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update”	136
THU-192 Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis	134
WED-347 Diagnosis of advanced liver fibrosis: the synergy of open data, synthetic data generation, CatBoost, and feature engineering	133
Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma	130
One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/β-catenin pathways in cholangiocarcinoma	129
MetALD accounts for a large part of what we call MASLD!	129
SAT-521 Impact of centre type on treatment and survival outcomes in hepatocellular carcinoma (HCC)	128
FRI-247 Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10, 000 patients	126
THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter regi	124
OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: t	123
FRI-195 Genetically determined circulating protein biomarkers and risk of advanced fibrosis	122
WED-257 FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis	121

THU-447 Incidence and predictors of complications following percutaneous liver biopsy: a multicenter study	120
WED-092 Hyperuricemia leads to early cognitive dysfunction and neuronal cell injury in bile-duct ligated rats	120
TOP-311-YI Subtypes of steatotic liver disease have differing clinical outcomes	118
WED-495 The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series	118
OS-004 Testing for hepatitis C virus infection in prisons in England: room for improvement	116
FRI-475-YI NADPH oxidase 1 inhibition as therapeutic strategy in hepatocellular carcinoma: insights from human-relevant models	115
WED-058-YI High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension	114
SAT-151-YI The role of interleukin-8 in primary sclerosing cholangitisassociated immune cell dysregulation	114
OS-111 Predictive genomic biomarkers for Atezolizumab plus Bevacizumab combination immunotherapy response in liver cancer: insights from the IMbrave150 trial	114
THU-099-YI Small duct primary sclerosing cholangitis is not associated with a heightened risk of colorectal cancer compared to inflammatory bowel disease alone	113
SAT-070 Argon plasma coagulation or endoscopic band ligation for gastric antral vascular ectasia: a randomized comparative analysis	113
SAT-479-YI Lower frequency of PNPLA3 in african populations and divergent associations with hepatocellular carcinoma	113
THU-219 Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele	113
FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis	112
THU-114 Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis	112
THU-040-YI Establishment of the irish hepatology nurses association: an association for nurses working in liver disease in Ireland	111
SAT-009 Increased prevalence of metabolic-alcohol liver disease in Europe and of metabolic dysfunction-associated steatotic liver disease in the Americas. Results of the global IMPROVEMENT study	111
WED-524-YI Multi-omics study of chronic liver diseases with rifaximin treatment	110
FRI-067 Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma	109
SAT-418 Prevalence of hepatitis C virus infection in a nursing home: a frequently overlooked submerged population	108
LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study	107
THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid	106
SAT-194 Effect of statin therapy in patients with obesity and cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) on pre-liver transplant mortality	106
FRI-245 Longitudinal follow-up of Fib-4 in patients at risk of steatotic liver disease (SLD) receiving low-dose Methotrexate treatment (LDMTX): results from the CIRT randomized placebo-controlled Tria	106
WED-483 Performance comparison of four hepatitis E antibodies detection methods	104
LBP-016 Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis	103
FRI-470 Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma	103
SAT-041 Real-world evidence of magnesium isoglycyrrhizinate for perioperative protection against hepatic injury in patients undergoing hepatectomy	103